Compare ADAG & GLQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADAG | GLQ |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 146.0M |
| IPO Year | 2020 | N/A |
| Metric | ADAG | GLQ |
|---|---|---|
| Price | $3.78 | $7.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 222.3K | 40.4K |
| Earning Date | 03-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3,688.61 | N/A |
| Revenue Next Year | $17.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $5.33 |
| 52 Week High | $4.58 | $8.38 |
| Indicator | ADAG | GLQ |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 35.57 |
| Support Level | $1.69 | $7.48 |
| Resistance Level | $4.58 | $7.92 |
| Average True Range (ATR) | 0.47 | 0.13 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 44.97 | 17.12 |
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.